pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline patients characteristics

Medication Total (n=215) p-value

Nivolumab (n=115) Pembrolizumab (n=100)
Age, mean (SD), years 61.2 (11.3) 58.9 (13.4) 60.1 (12.4) 0.182
Sex, n (%) 0.567
Male 78 (67.8) 64 (64.0) 142 (66.0)
Female 37 (32.2) 36 (100.0) 73 (34.0)
Height, mean (SD), cm 163.4 (8.1) 164.5 (9.0) 163.9 (8.5) 0.352
Weight, mean (SD), kg 61.3 (11.4) 62.1 (12.4) 61.7 (11.8) 0.614
BMI, mean (SD), kg/m2 22.9 (3.5) 22.8 (3.3) 22.9 (3.4) 0.916
Cancer type, n (%) <0.001*
NSCLC 67 (58.3) 51 (51.0) 118 (54.9)
Malignant melanoma 13 (11.3) 20 (20.0) 33 (15.3)
Lymphoma 0 (0.0) 17 (17.0) 17 (7.9)
AGC 14 (12.2) 0 (0.0) 14 (6.5)
Colon ca 5 (4.3) 0 (0.0) 5 (2.3)
RCC 5 (4.3) 0 (0.0) 5 (2.3)
Bladder ca 0 (0.0) 5 (5.0) 5 (2.3)
HCC 3 (2.6) 1 (1.0) 4 (1.9)
Others 8 (7.0)1) 6 (6.0)2) 14 (6.5)
ECOG Performance status, n (%) 0.095
0 2 (1.7) 8 (8.0) 10 (4.7)
1 93 (80.9) 79 (79.0) 172 (80.0)
2 19 (16.5) 13 (13.0) 32 (14.9)
3 1 (0.9) 0 (0.0) 1 (0.5)
Diabetes Mellitus, n (%) 0.472
Yes 22 (19.1) 15 (15.0) 37 (17.2)
No 93 (80.9) 85 (85.0) 178 (82.8)
Hypertension, n (%) 0.281
Yes 35 (30.4) 23 (23.0) 58 (27.0)
No 80 (69.6) 77 (77.0) 157 (73.0)
PD-L1 expression, n (%) <0.001*
Positive 7 (17.9) 43 (78.2) 50 (53.2)
Negative 32 (82.1) 12 (21.8) 44 (46.8)
Prior chemotherapy regimens, median (range) 2 (0-9) 2 (0-8) 2 (0-9) 0.075

SD, standard deviation; BMI, Body Mass Index; ECOG PS, Eastern Cooperative Oncology Group; NSCLC, Non-small cell lung cancer; PD-L1, Programmed death-ligand 1

1)Others : Leiomyosarcoma 1; Prostate ca 1; Ureter Ca 1; SCLC 1; Cervical ca 1; Rectal Ca 1; Cholangiocarcinoma 1; Ovary cancer 1

2)Others : Cervical cancer of squamous cell carcinoma 1; Transitional cell carcinoma, ureter 1; Lt. hypopharyngeal cancer 1; Hepatocellular carcinoma 1; Cholangiocarcinoma 1; Bladder cancer 1; Renal pelvis TCC 1; Glioblastoma of brain 1

*indicates P<0.05

Korean J Clin Pharm 2021;31:188-97 https://doi.org/10.24304/kjcp.2021.31.3.188
© 2021 Korean J Clin Pharm